Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



Theranexus plans to extend its phase 2 pipeline with a third program

15/10/2018
Download PDF File (382 Ko)

Theranexus announces that Rodolphe Besserve will join its Board of Directors

11/10/2018
Download PDF File (368 Ko)

Theranexus announces a new European patent protecting THN201, its drug candidate for the treatment of neurocognitive disorders including those associated with Alzheimers

09/10/2018
Download PDF File (373 Ko)

 Recognition of the scientific excellence of Theranexus

01/10/2018
Download PDF File (379 Ko)

Theranexus announces its first half 2018 results

27/09/2018
Download PDF File (335 Ko)

December 4th & 5th 2018 : European MidCap Event, Geneva

January 22nd 2019: Biomed conference, Paris